Anovent
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Anovent - overview
Established
2017
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2017 and based in Shanghai, China, Anovent operates as a pharmaceutical company that focuses on the development and production of inhalation soft mist products. It has applied for 14 patents. In November 2019, Anovent closed a strategic investment from new investor China Sequoia Capital. The company is mainly engaged in the research and development and production of inhalation soft mist products.
The main products are first-generation generic drugs, 505(b)2 and innovative drugs for inhalation soft mists. The company also provides technical product solutions for the domestic and foreign preparation/inhalation industries. The company generates revenue by providing inhalation soft mist products.
Current Investors
Hong Shan
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.anovent.com
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.